FBR & Co reissued their outperform rating on shares of Prima BioMed Ltd. (NASDAQ:PBMD) in a report issued on Friday. The firm currently has a $6.00 price target on the stock.
Immutep Ltd. buy Quitte
Start price
21.07.16
/
50%
€0.15
Target price
23.01.17
€0.20
Performance (%)
-13.33%
End price
23.01.17
€0.13
Summary
This prediction ended on 23.01.17 with a price of €0.13. The price of Immutep Ltd. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -13.33%. Quitte has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Immutep Ltd. | 0.000% | 0.000% | -82.292% | -85.912% |
| iShares Core DAX® | 1,72 % | 3,37 % | 5,89 % | 52,38 % |
| iShares Nasdaq 100 | -4,56 % | -4,24 % | 21,39 % | 72,45 % |
| iShares Nikkei 225® | -7,12 % | -11,87 % | 42,36 % | 57,58 % |
| iShares S&P 500 | -0,89 % | 1,69 % | 19,49 % | 62,15 % |
Comments by Quitte for this prediction
In the thread Immutep Ltd. diskutieren
wer wagt ....
(Laufzeit überschritten)